Navigation Links
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
Date:5/31/2014

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.

"These are optimistic results for one of the first targeted therapies for cancer stem cells," says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell-Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site. "And it is great to work with such a science-focused sponsor, whose vision aligns with ours: bringing to the clinic cutting-edge drugs and ideas that are focused on targeting CSCs. In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors."

OMP-54F28 (FZD8-Fc) is an antagonist of the Wnt pathway, a key CSC signaling pathway that regulates the fate of these cells. The Wnt pathway is known to be inappropriately activated in many major tumor types, including colon, breast, liver, lung and pancreatic cancers, and is critical for the function of CSCs. Because of this extensive validation, in the Jimeno lab and elsewhere, the Wnt pathway has been a major focus of anti-cancer drug discovery efforts. OMP-54F28 (FZD8-Fc) and a sister compound also developed by OncoMed, vantictumab (OMP-18R5), are two of the first therapeutic agents targeting t
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. ChromaDex® Announces Financial Results for the Year Ended 2011
2. Aware, Inc. Reports First Quarter 2012 Financial Results
3. Better housing conditions for zebrafish could improve research results
4. NIH-led study finds genetic test results do not trigger increased use of health services
5. New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge
6. Study results: Adult stem cells from bone marrow
7. SF State researcher releases first results from nationwide bee count
8. Aware, Inc. Reports Second Quarter 2012 Financial Results
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. Aware, Inc. Reports Third Quarter 2012 Financial Results
11. Consumers have few negative reactions to the results of genetic testing for cancer mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... tomorrow (14 October) as CSIRO launches in the United ... 2006 in Atlanta, Georgia, the world's largest conference for ... mathematical method, patented by Australia's CSIRO, for automatically tracing ... With up to 40,000 delegates expected, the conference will ...
... for treating a recurrent cancer of the central nervous ... glioma, has shown promising results in preliminary data from ... from the first group of six patients in the ... Center, showed that vitespen (trademarked as Oncophage), a vaccine ...
... a few dozen trillions, a human adult has about 70 ... 959 cells. , Yet we have an awful lot ... been exploring two “highly conserved? cell-signaling pathways for innate immunity ... a lot of common enemies, particularly soil-borne pathogens. C. elegans, ...
Cached Biology News:Vaccine for brain tumors shows promising results 2Vaccine for brain tumors shows promising results 3Worms produce surprise insight into human fever 2
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... of molecular diagnostic test results. It also enables ... for the validation and reporting of high profile ... diagnostics is a rapidly growing area of biotechnology ... genetic predisposition, cancer, and companion diagnostics in personalized ...
(Date:7/23/2014)... 23, 2014  Sangamo BioSciences, Inc. (NASDAQ: ... results and accomplishments. For the second ... net loss of $7.0 million, or $0.10 per share, ... $0.10 per share, for the same period in 2013. ... cash equivalents, marketable securities and interest receivable of $236.7 ...
(Date:7/23/2014)... the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University of ... succeeded in embedding nearly perfect semiconductor crystals into ... producing hybrid nanowires, very fast and multi-functional processing ... in the future. The research results will be ... , Nano-optoelectronics are considered the cornerstone of future ...
(Date:7/23/2014)... 23, 2014 Shimadzu Scientific Instruments ... acid analysis system developed jointly with Ajinomoto Co. ... can analyze 38 amino acids in nine minutes, ... achieves high-speed analysis utilizing a fast application-specific column ... accurate analytical results even under conditions with difficult ...
Breaking Biology Technology:New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2
... SAN DIEGO, CA, July 30, 2009 Senomyx, Inc. (Nasdaq: ... on Tuesday, August 4, 2009 before the opening of the U.S. financial ... Internet broadcast that will provide a corporate update and a review of ... Time (8:00 a.m. Pacific Time). , , To participate ...
... , , ALPHARETTA, Ga., July ... announced the appointment of Philip Vogt as Executive Vice President, ... more than thirty years of pharmaceutical experience and will ... to this role, Vogt served as President of Ethex Corporation ...
... SOUTH SAN FRANCISCO, Calif., July 30 Sunesis Pharmaceuticals, ... on the development and commercialization of new oncology therapeutics for ... NASDAQ has approved its application to transfer the listing of ... NASDAQ Capital Market. The transfer will be effective at the ...
Cached Biology Technology:SENOMYX, INC. SECOND QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 4, 2009 2Sunesis Receives Approval for Listing on The NASDAQ Capital Market 2Sunesis Receives Approval for Listing on The NASDAQ Capital Market 3
ID clarifier: platform...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is used for vertical electrophoresis applications. The cell accommodates ... L of running buffer. It includes the PROTEAN II ... kit, which contains accessories for use with 2.0 mm ... 2 sets of 20 x 20 cm glass plates, ...
Biology Products: